Literature DB >> 3671711

Skeletal metastases.

J H Thrall1, B I Ellis.   

Abstract

This article discusses the role of imaging in the evaluation of patients with known or suspected malignancies. The radionuclide skeletal scintigram is the most sensitive imaging method for screening the skeleton for metastatic disease but is inherently nonspecific. Standard radiography provides useful correlative information and often confirms the presence of malignancy when characteristic lytic or blastic lesions are seen. Newer modalities such as CT and MR do not have a primary role in detecting skeletal metastases but may reveal lesions incidentally.

Entities:  

Mesh:

Year:  1987        PMID: 3671711

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  5 in total

1.  Radiology rounds. Benign bone islands.

Authors:  M K McLennan
Journal:  Can Fam Physician       Date:  1996-10       Impact factor: 3.275

2.  Utility of SPECT imaging for determination of vertebral metastases in patients with known primary tumors.

Authors:  D L Bushnell; D Kahn; B Huston; C G Bevering
Journal:  Skeletal Radiol       Date:  1995-01       Impact factor: 2.199

3.  Downregulation of matrix metalloproteinase-2 (MMP-2) utilizing adenovirus-mediated transfer of small interfering RNA (siRNA) in a novel spinal metastatic melanoma model.

Authors:  Andrew J Tsung; Odysseas Kargiotis; Chandramu Chetty; Sajani S Lakka; Meena Gujrati; Daniel G Spomar; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2008-03       Impact factor: 5.650

4.  Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning.

Authors:  F Michel; M Solèr; E Imhof; A P Perruchoud
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

5.  Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.

Authors:  Mehmet Halit Yilmaz; Mustafa Ozguroglu; Devrim Mert; Hande Turna; Gökhan Demir; Ibrahim Adaletli; Sila Ulus; Metin Halac; Kaya Kanberoğlu
Journal:  Med Oncol       Date:  2007-11-27       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.